Skip to main content

Table 1 Clinical characteristics of patients with early deterioration

From: Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern

  Baseline Time to endpoint (weeks) Change at endpoint compared to baseline Response to other treatments
  MRC GS INCAT-SS   ΔINCAT-DS ΔRMI ΔMRC ΔGS Δ INCAT-SS  
1/D 48 51 np 5 1 -4 -2 -15 npa P
2/D 53 108 5 6 1 0 5 -52 -3 No
3/D 47 18 3 1 3 -7 -5 -5 1 IVIg
4/D 52 125 2 1 4 -10 -7 -25 0 IVIg
5/P 48 47 7 8 4 -7 -6 -27 -2 IVIg
6/P 50 9 11 2 3 -2 np np np P
7/P 51 83 9 4 2 0 1 -47 5 No
  1. Legend: Abbreviations: D dexamethasone, P prednisolone, np not performed, MRC Medical Research Council Sum Score (maximum of 60), MGS Mean Grip Strength (mean of both arms, Vigorimeter) INCAT-DS, Inflammatory Neuropathy Cause and Treatment Disability Scale (maximum score of 10, higher scores represent more disability), RMI Rivermead Mobility Index (maximum score of 15, higher scores represent less disability), INCAT-SS Inflammatory Neuropathy Cause and Treatment Sensory Sum Score (maximum score of 20, higher scores represent more sensory deficit). aINCAT-SS in this patient at time of deterioration was 10.